Global Oncology Based Molecular Diagnostics Market Size Study & Forecast, by Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Others), by Product (Instruments, Reagents, Others), by Technology (PCR, In situ hybridization, INAAT, Chips and microarrays, Mass spectrometry, Sequencing, TMA, Others), and Regional Analysis, 2023-2030
Global Oncology Based Molecular Diagnostics Market is valued at approximately USD 2.44 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 12.1% over the forecast period 2023-2030. Oncology-centric molecular diagnostics is a specialized field of medical diagnostics dedicated to pinpointing and scrutinizing precise molecular and genetic alterations linked to cancer. This diagnostic discipline entails the scrutiny of DNA, RNA, proteins, and other molecular components, aiming to comprehend the molecular intricacies that drive the evolution, advancement, and reaction to treatment in cancer. Integral to the realm of personalized medicine, oncology-based molecular diagnostics customizes treatment approaches by leveraging insights derived from the distinct molecular attributes of an individual's cancer. The increasing operational costs and regulatory requirements, coupled with reimbursement scenarios for key countries are the key factors that are contributing to the market growth on the global scale.
Additionally, the surge in the prevalence of cancer worldwide is a key factor that is fueling the demand for oncology-based molecular diagnostics, which is leveraging the market growth prospects. According to the World Health Organization, in 2020, it was estimated that nearly 19.3 million new cases of cancer were recorded globally, which is projected to rise and is likely to reach 30.2 million new cases by 2040. These substantial figures underscore the escalating prevalence of cancer, emphasizing the growing imperative for early detection and preventive healthcare. Consequently, soaring demand for oncology molecular diagnostic tests is propelling the growth of the Oncology Based Molecular Diagnostics Market over the estimated period. Moreover, the surge in adoption of new software solutions, as well as increasing demand for point-of-care treatment present various lucrative opportunities over the forecast years. However, the high cost of molecular diagnostic tests, along with a lack of skilled workforce and stringent regulatory framework are challenging the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Oncology Based Molecular Diagnostics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rapid adoption of advanced diagnostic techniques, coupled with the prevalence of sedentary lifestyles and favorable health reimbursement, which has contributed to the growth of the Oncology Molecular Diagnostics Market. According to a 2020 report from the American Cancer Society, various professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have formulated guidelines for biomarker testing and treatment. Furthermore, the escalating incidence of cancer in the country contributes significantly to the growth of the Oncology Molecular Diagnostics Market in the region. The 2020 statistics from the National Cancer Institute (NCI) reveal that approximately 1,806,590 cancer cases were diagnosed in the United States in 2020, and it is anticipated that the number of cancer survivors is expected to reach 2.2 million by 2030. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The rising technological advancements in diagnostic testing, increasing cases of cancer, and increasing demand for point-of-care treatment are significantly propelling the market demand across the region.
Major market players included in this report are:
Abbott
Bayer AG
Becton, Dickinson and Company
Cepheid
Agilent Technologies, Inc.
Danaher Corporation
Hologic, Inc.
Qiagen
F. Hoffmann-La Roche Ltd.
Siemens
Recent Developments in the Market:
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
Others
By Product:
Instruments
Reagents
Others
By Technology:
PCR
In situ hybridization
INAAT
Chips and microarrays
Mass spectrometry
Sequencing
TMA
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
Additionally, the surge in the prevalence of cancer worldwide is a key factor that is fueling the demand for oncology-based molecular diagnostics, which is leveraging the market growth prospects. According to the World Health Organization, in 2020, it was estimated that nearly 19.3 million new cases of cancer were recorded globally, which is projected to rise and is likely to reach 30.2 million new cases by 2040. These substantial figures underscore the escalating prevalence of cancer, emphasizing the growing imperative for early detection and preventive healthcare. Consequently, soaring demand for oncology molecular diagnostic tests is propelling the growth of the Oncology Based Molecular Diagnostics Market over the estimated period. Moreover, the surge in adoption of new software solutions, as well as increasing demand for point-of-care treatment present various lucrative opportunities over the forecast years. However, the high cost of molecular diagnostic tests, along with a lack of skilled workforce and stringent regulatory framework are challenging the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Oncology Based Molecular Diagnostics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rapid adoption of advanced diagnostic techniques, coupled with the prevalence of sedentary lifestyles and favorable health reimbursement, which has contributed to the growth of the Oncology Molecular Diagnostics Market. According to a 2020 report from the American Cancer Society, various professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have formulated guidelines for biomarker testing and treatment. Furthermore, the escalating incidence of cancer in the country contributes significantly to the growth of the Oncology Molecular Diagnostics Market in the region. The 2020 statistics from the National Cancer Institute (NCI) reveal that approximately 1,806,590 cancer cases were diagnosed in the United States in 2020, and it is anticipated that the number of cancer survivors is expected to reach 2.2 million by 2030. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The rising technological advancements in diagnostic testing, increasing cases of cancer, and increasing demand for point-of-care treatment are significantly propelling the market demand across the region.
Major market players included in this report are:
Abbott
Bayer AG
Becton, Dickinson and Company
Cepheid
Agilent Technologies, Inc.
Danaher Corporation
Hologic, Inc.
Qiagen
F. Hoffmann-La Roche Ltd.
Siemens
Recent Developments in the Market:
- In December 2021, QIAGEN entered a collaboration with Denovo Biopharma to develop a companion diagnostic test for the management of diffuse large B-cell lymphoma. This diagnostic test aims to identify individuals carrying the Denovo Genomic Marker 1 (DGM1), which corresponds to the company's cancer treatment, DB102 drug.
- In December 2020, Veracyte Inc. and Bayer AG partnered to enhance the Precision Oncology Patient Identification Program, specifically in the realm of thyroid cancer. This collaboration aims to facilitate testing using Veracyte's Afirma Xpression Atlas (XA), designed to pinpoint the genomic drivers within tumor cells. The focus may be on individuals with advanced thyroid cancer, to identify biomarker-driven therapies for their benefit.
- Historical Data – 2020 - 2021
- Base Year for Estimation – 2022
- Forecast period - 2023-2030
- Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered - Type, Product, Technology, Region
- Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
Others
By Product:
Instruments
Reagents
Others
By Technology:
PCR
In situ hybridization
INAAT
Chips and microarrays
Mass spectrometry
Sequencing
TMA
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Oncology Based Molecular Diagnostics Market, by Region, 2020-2030 (USD Billion)
1.2.2. Oncology Based Molecular Diagnostics Market, by Type, 2020-2030 (USD Billion)
1.2.3. Oncology Based Molecular Diagnostics Market, by Product, 2020-2030 (USD Billion)
1.2.4. Oncology Based Molecular Diagnostics Market, by Technology, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET DYNAMICS
3.1. Oncology Based Molecular Diagnostics Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Reimbursement scenario for key countries
3.1.1.2. Rising demand for Point-of-care treatment
3.1.2. Market Challenges
3.1.2.1. High cost of molecular diagnostic tests
3.1.2.2. Lack of skilled workforce and stringent regulatory framework
3.1.3. Market Opportunities
3.1.3.1. Surge in adoption of novel software solutions
3.1.3.2. Increasing demand for point-of-care treatment
CHAPTER 4. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET, BY TYPE
5.1. Market Snapshot
5.2. Global Oncology Based Molecular Diagnostics Market by Type, Performance - Potential Analysis
5.3. Global Oncology Based Molecular Diagnostics Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
5.4. Oncology Based Molecular Diagnostics Market, Sub Segment Analysis
5.4.1. Breast Cancer
5.4.2. Prostate Cancer
5.4.3. Colorectal Cancer
5.4.4. Cervical Cancer
5.4.5. Liver Cancer
5.4.6. Lung Cancer
5.4.7. Blood Cancer
5.4.8. Kidney Cancer
5.4.9. Others
CHAPTER 6. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT
6.1. Market Snapshot
6.2. Global Oncology Based Molecular Diagnostics Market by Product, Performance - Potential Analysis
6.3. Global Oncology Based Molecular Diagnostics Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
6.4. Oncology Based Molecular Diagnostics Market, Sub Segment Analysis
6.4.1. Instruments
6.4.2. Reagents
6.4.3. Others
CHAPTER 7. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1. Market Snapshot
7.2. Global Oncology Based Molecular Diagnostics Market by Technology, Performance - Potential Analysis
7.3. Global Oncology Based Molecular Diagnostics Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
7.4. Oncology Based Molecular Diagnostics Market, Sub Segment Analysis
7.4.1. PCR
7.4.2. In situ hybridization
7.4.3. INAAT
7.4.4. Chips and microarrays
7.4.5. Mass spectrometry
7.4.6. Sequencing
7.4.7. TMA
7.4.8. Others
CHAPTER 8. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET, REGIONAL ANALYSIS
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Oncology Based Molecular Diagnostics Market, Regional Market Snapshot
8.4. North America Oncology Based Molecular Diagnostics Market
8.4.1. U.S. Oncology Based Molecular Diagnostics Market
8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
8.4.1.2. Product breakdown estimates & forecasts, 2020-2030
8.4.1.3. Technology breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Oncology Based Molecular Diagnostics Market
8.5. Europe Oncology Based Molecular Diagnostics Market Snapshot
8.5.1. U.K. Oncology Based Molecular Diagnostics Market
8.5.2. Germany Oncology Based Molecular Diagnostics Market
8.5.3. France Oncology Based Molecular Diagnostics Market
8.5.4. Spain Oncology Based Molecular Diagnostics Market
8.5.5. Italy Oncology Based Molecular Diagnostics Market
8.5.6. Rest of Europe Oncology Based Molecular Diagnostics Market
8.6. Asia-Pacific Oncology Based Molecular Diagnostics Market Snapshot
8.6.1. China Oncology Based Molecular Diagnostics Market
8.6.2. India Oncology Based Molecular Diagnostics Market
8.6.3. Japan Oncology Based Molecular Diagnostics Market
8.6.4. Australia Oncology Based Molecular Diagnostics Market
8.6.5. South Korea Oncology Based Molecular Diagnostics Market
8.6.6. Rest of Asia Pacific Oncology Based Molecular Diagnostics Market
8.7. Latin America Oncology Based Molecular Diagnostics Market Snapshot
8.7.1. Brazil Oncology Based Molecular Diagnostics Market
8.7.2. Mexico Oncology Based Molecular Diagnostics Market
8.8. Middle East & Africa Oncology Based Molecular Diagnostics Market
8.8.1. Saudi Arabia Oncology Based Molecular Diagnostics Market
8.8.2. South Africa Oncology Based Molecular Diagnostics Market
8.8.3. Rest of Middle East & Africa Oncology Based Molecular Diagnostics Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Company
9.1.2. Company
9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Abbott
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Bayer AG
9.3.3. Becton, Dickinson and Company
9.3.4. Cepheid
9.3.5. Agilent Technologies, Inc.
9.3.6. Danaher Corporation
9.3.7. Hologic, Inc.
9.3.8. Qiagen
9.3.9. F. Hoffmann-La Roche Ltd.
9.3.10. Siemens
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Oncology Based Molecular Diagnostics Market, by Region, 2020-2030 (USD Billion)
1.2.2. Oncology Based Molecular Diagnostics Market, by Type, 2020-2030 (USD Billion)
1.2.3. Oncology Based Molecular Diagnostics Market, by Product, 2020-2030 (USD Billion)
1.2.4. Oncology Based Molecular Diagnostics Market, by Technology, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET DYNAMICS
3.1. Oncology Based Molecular Diagnostics Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Reimbursement scenario for key countries
3.1.1.2. Rising demand for Point-of-care treatment
3.1.2. Market Challenges
3.1.2.1. High cost of molecular diagnostic tests
3.1.2.2. Lack of skilled workforce and stringent regulatory framework
3.1.3. Market Opportunities
3.1.3.1. Surge in adoption of novel software solutions
3.1.3.2. Increasing demand for point-of-care treatment
CHAPTER 4. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET, BY TYPE
5.1. Market Snapshot
5.2. Global Oncology Based Molecular Diagnostics Market by Type, Performance - Potential Analysis
5.3. Global Oncology Based Molecular Diagnostics Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
5.4. Oncology Based Molecular Diagnostics Market, Sub Segment Analysis
5.4.1. Breast Cancer
5.4.2. Prostate Cancer
5.4.3. Colorectal Cancer
5.4.4. Cervical Cancer
5.4.5. Liver Cancer
5.4.6. Lung Cancer
5.4.7. Blood Cancer
5.4.8. Kidney Cancer
5.4.9. Others
CHAPTER 6. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT
6.1. Market Snapshot
6.2. Global Oncology Based Molecular Diagnostics Market by Product, Performance - Potential Analysis
6.3. Global Oncology Based Molecular Diagnostics Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
6.4. Oncology Based Molecular Diagnostics Market, Sub Segment Analysis
6.4.1. Instruments
6.4.2. Reagents
6.4.3. Others
CHAPTER 7. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1. Market Snapshot
7.2. Global Oncology Based Molecular Diagnostics Market by Technology, Performance - Potential Analysis
7.3. Global Oncology Based Molecular Diagnostics Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
7.4. Oncology Based Molecular Diagnostics Market, Sub Segment Analysis
7.4.1. PCR
7.4.2. In situ hybridization
7.4.3. INAAT
7.4.4. Chips and microarrays
7.4.5. Mass spectrometry
7.4.6. Sequencing
7.4.7. TMA
7.4.8. Others
CHAPTER 8. GLOBAL ONCOLOGY BASED MOLECULAR DIAGNOSTICS MARKET, REGIONAL ANALYSIS
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Oncology Based Molecular Diagnostics Market, Regional Market Snapshot
8.4. North America Oncology Based Molecular Diagnostics Market
8.4.1. U.S. Oncology Based Molecular Diagnostics Market
8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
8.4.1.2. Product breakdown estimates & forecasts, 2020-2030
8.4.1.3. Technology breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Oncology Based Molecular Diagnostics Market
8.5. Europe Oncology Based Molecular Diagnostics Market Snapshot
8.5.1. U.K. Oncology Based Molecular Diagnostics Market
8.5.2. Germany Oncology Based Molecular Diagnostics Market
8.5.3. France Oncology Based Molecular Diagnostics Market
8.5.4. Spain Oncology Based Molecular Diagnostics Market
8.5.5. Italy Oncology Based Molecular Diagnostics Market
8.5.6. Rest of Europe Oncology Based Molecular Diagnostics Market
8.6. Asia-Pacific Oncology Based Molecular Diagnostics Market Snapshot
8.6.1. China Oncology Based Molecular Diagnostics Market
8.6.2. India Oncology Based Molecular Diagnostics Market
8.6.3. Japan Oncology Based Molecular Diagnostics Market
8.6.4. Australia Oncology Based Molecular Diagnostics Market
8.6.5. South Korea Oncology Based Molecular Diagnostics Market
8.6.6. Rest of Asia Pacific Oncology Based Molecular Diagnostics Market
8.7. Latin America Oncology Based Molecular Diagnostics Market Snapshot
8.7.1. Brazil Oncology Based Molecular Diagnostics Market
8.7.2. Mexico Oncology Based Molecular Diagnostics Market
8.8. Middle East & Africa Oncology Based Molecular Diagnostics Market
8.8.1. Saudi Arabia Oncology Based Molecular Diagnostics Market
8.8.2. South Africa Oncology Based Molecular Diagnostics Market
8.8.3. Rest of Middle East & Africa Oncology Based Molecular Diagnostics Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Company
9.1.2. Company
9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Abbott
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Bayer AG
9.3.3. Becton, Dickinson and Company
9.3.4. Cepheid
9.3.5. Agilent Technologies, Inc.
9.3.6. Danaher Corporation
9.3.7. Hologic, Inc.
9.3.8. Qiagen
9.3.9. F. Hoffmann-La Roche Ltd.
9.3.10. Siemens
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Oncology Based Molecular Diagnostics Market, report scope
TABLE 2. Global Oncology Based Molecular Diagnostics Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Oncology Based Molecular Diagnostics Market estimates & forecasts by Type 2020-2030 (USD Billion)
TABLE 4. Global Oncology Based Molecular Diagnostics Market estimates & forecasts by Product 2020-2030 (USD Billion)
TABLE 5. Global Oncology Based Molecular Diagnostics Market estimates & forecasts by Technology 2020-2030 (USD Billion)
TABLE 6. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. U.S. Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 20. Canada Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. Canada Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 23. UK Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. UK Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 26. Germany Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. Germany Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 29. France Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. France Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 32. Italy Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Italy Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 35. Spain Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. Spain Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 38. RoE Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. RoE Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 41. China Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. China Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 44. India Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. India Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 47. Japan Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. Japan Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 50. South Korea Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. South Korea Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 53. Australia Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. Australia Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 56. RoAPAC Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. RoAPAC Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 59. Brazil Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Brazil Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 62. Mexico Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. Mexico Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 65. RoLA Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. RoLA Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. Saudi Arabia Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 68. South Africa Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. RoMEA Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Oncology Based Molecular Diagnostics Market
TABLE 71. List of primary sources, used in the study of global Oncology Based Molecular Diagnostics Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Oncology Based Molecular Diagnostics Market, report scope
TABLE 2. Global Oncology Based Molecular Diagnostics Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Oncology Based Molecular Diagnostics Market estimates & forecasts by Type 2020-2030 (USD Billion)
TABLE 4. Global Oncology Based Molecular Diagnostics Market estimates & forecasts by Product 2020-2030 (USD Billion)
TABLE 5. Global Oncology Based Molecular Diagnostics Market estimates & forecasts by Technology 2020-2030 (USD Billion)
TABLE 6. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Oncology Based Molecular Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Oncology Based Molecular Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. U.S. Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 20. Canada Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. Canada Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 23. UK Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. UK Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 26. Germany Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. Germany Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 29. France Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. France Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 32. Italy Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Italy Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 35. Spain Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. Spain Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 38. RoE Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. RoE Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 41. China Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. China Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 44. India Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. India Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 47. Japan Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. Japan Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 50. South Korea Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. South Korea Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 53. Australia Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. Australia Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 56. RoAPAC Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. RoAPAC Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 59. Brazil Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Brazil Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 62. Mexico Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. Mexico Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 65. RoLA Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. RoLA Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. Saudi Arabia Oncology Based Molecular Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 68. South Africa Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. RoMEA Oncology Based Molecular Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Oncology Based Molecular Diagnostics Market
TABLE 71. List of primary sources, used in the study of global Oncology Based Molecular Diagnostics Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Oncology Based Molecular Diagnostics Market, research methodology
FIG 2. Global Oncology Based Molecular Diagnostics Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Oncology Based Molecular Diagnostics Market, key trends 2022
FIG 5. Global Oncology Based Molecular Diagnostics Market, growth prospects 2023-2030
FIG 6. Global Oncology Based Molecular Diagnostics Market, porters 5 force model
FIG 7. Global Oncology Based Molecular Diagnostics Market, pest analysis
FIG 8. Global Oncology Based Molecular Diagnostics Market, value chain analysis
FIG 9. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Oncology Based Molecular Diagnostics Market, regional snapshot 2020 & 2030
FIG 15. North America Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
FIG 16. Europe Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Oncology Based Molecular Diagnostics Market, research methodology
FIG 2. Global Oncology Based Molecular Diagnostics Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Oncology Based Molecular Diagnostics Market, key trends 2022
FIG 5. Global Oncology Based Molecular Diagnostics Market, growth prospects 2023-2030
FIG 6. Global Oncology Based Molecular Diagnostics Market, porters 5 force model
FIG 7. Global Oncology Based Molecular Diagnostics Market, pest analysis
FIG 8. Global Oncology Based Molecular Diagnostics Market, value chain analysis
FIG 9. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Oncology Based Molecular Diagnostics Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Oncology Based Molecular Diagnostics Market, regional snapshot 2020 & 2030
FIG 15. North America Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
FIG 16. Europe Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Oncology Based Molecular Diagnostics Market 2020 & 2030 (USD Billion)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
